Supplementary Table S1. SEC-MALS analysis results of the mutant $\alpha\gamma_{\Delta N}$ heterodimer, the mutant $\alpha_2\beta\gamma_{\Delta N}$ heterotetramer, and the mutant $\alpha_2\beta_{mut}\gamma$ heterooctamer in comparison with wild-type $\alpha\beta$ and $\alpha\gamma$ heterodimers and wild-type $\alpha_2\beta\gamma$ heterooctamer.

Enzyme	Apparent molect	Dafaranaa		
	2 mg/ml	12 mg/ml	Reference	
αβ	79	126	[35]	
αγ	79	130	[35]	
$lpha\gamma_{\Delta N}$	84	123	This work	
$\alpha_2\beta\gamma_{\Delta N}$	106	125	This work	
$\alpha_2\beta_{mut}\gamma$	297	281	This work	
α2βγ	284	283	This work	

Supplementary Table S2. Enzymatic activities and kinetic parameters of wild-type and β-mutant HsIDH3^a.

Enzyme	No activators				With activators (CIT+ADP)	
	V _{max,ICT} (µmol/min/mg)	S _{0.5,ICT} (mM)	S0.5,Mn (µM)	S _{0.5,NAD} (μM)	V _{max,ICT} (μmol/min/mg)	S0.5,ICT (mM)
Wild-type HsIDH3	28.6±0.3	3.54±0.18	77.6±8.0	242±42	30.6±1.0	0.43±0.03
β-mutant HsIDH3	27.7±0.6	2.82±0.21	63.8±6.8	182±56	34.0±1.5	0.40±0.08

^a The enzymatic activities and kinetic parameters of wild-type and β -mutant HsIDH3 were measured at the standard conditions with varied concentrations of the substrate ICT, the metal ion Mn²⁺, or the co-factor NAD.

Supplementary Fig. S1 SEC and SDS-PAGE analyses of wild-type and mutant HsIDH3. (a) SEC analyses (Superdex 200 10/300 GL column) of wild-type (Wt) HsIDH3 ($\alpha_2\beta\gamma$), the β -mutant (β -mut) HsIDH3 ($\alpha_2\beta_{mut}\gamma$), and the HsIDH3 mutants containing point mutations at the allosteric site, the pseudo allosteric site, the heterodimer interface, and the heterodimer-heterodimer interface, as well as the mutant $\alpha\gamma_{\Delta N}$ heterodimer and the mutant $\alpha\beta\alpha\gamma_{\Delta N}$ heterotetramer. The abbreviations of the mutants are the same as in Table 2. (b) SDS-PAGE (12%) analyses of wild-type and mutant HsIDH3. M: molecular mass markers. The upper band represents the β (39 kDa) and γ subunits (39 kDa), and the lower band represents the α subunit (37 kDa).







Supplementary Fig. S2 SEC-MALS analyses of the mutant $\alpha_{\gamma\Delta N}$ heterodimer, the mutant $\alpha_2\beta_{\gamma\Delta N}$ heterotetramer, and the mutant $\alpha_2\beta_{mut}\gamma$ heterooctamer of HsIDH3. (a) SEC-MALS analyses of the mutant $\alpha_2\beta_{\gamma\Delta N}$ heterotetramer at concentrations of 2 mg/ml and 12 mg/ml. (b) SEC-MALS analyses of the mutant $\alpha_2\beta_{\gamma\Delta N}$ heterotetramer at concentrations of 2 mg/ml and 12 mg/ml. (c) SEC-MALS analyses of the β -mutant HsIDH3 ($\alpha_2\beta_{mut}\gamma$) at concentrations of 2 mg/ml and 12 mg/ml. (d) SEC-MALS analyses of wild-type HsIDH3 ($\alpha_2\beta\gamma$) at concentrations of 2 mg/ml and 12 mg/ml. (d) SEC-MALS analyses of wild-type HsIDH3 ($\alpha_2\beta\gamma$) at concentrations of 2 mg/ml and 12 mg/ml. (d) SEC-MALS analyses of wild-type HsIDH3 ($\alpha_2\beta\gamma$) at concentrations of 2 mg/ml and 12 mg/ml. Thromatograms show the readings from the light scattering (red) at 90°, the refractive index (violet), and the UV (green) detectors. The left and right vertical axes represent the light scattering detector reading and the molecular mass.



Supplementary Fig. S3 Saturation curves of wild-type and mutant HsIDH3. (a) ICT saturation curves of wild-type (Wt) HsIDH3 ($\alpha_2\beta\gamma$) (left panel) and the β -mutant (β -mut) HsIDH3 ($\alpha_2\beta_{mut}\gamma$) (right panel) in the absence and presence of the activators (CIT and ADP). (b) Mn²⁺ saturation curves of wild-type HsIDH3 and the β -mutant HsIDH3 (left panel) and NAD saturation curves of wild-type HsIDH3 and the β -mutant HsIDH3 (left panel) and NAD saturation curves of the HsIDH3 mutants containing point mutations at the allosteric site, the pseudo allosteric site, the heterodimer interface, and the heterodimer-heterodimer interface in the absence and presence of the activators (CIT and ADP). The abbreviations of the mutants are the same as in Table 2. The activities were measured at the standard conditions with varied concentrations of the substrate ICT, the metal ion Mn²⁺, or the cofactor NAD. The values are the averages of two independent measurements with the standard errors.



Supplementary Fig. S4 Simulated annealing composite omit maps (contoured at 1.0 σ level) of several representative regions in the structure of the apo β -mutant HsIDH3. (a) The clasp domain of the $\alpha\beta$ heterodimer (left) and the $\alpha\gamma$ heterodimer (right). (b) The back cleft of the β subunit. (c) The N-terminal of the γ subunit. (d) The N-terminal regions of the $\alpha7$ helices of the $\alpha\beta$ heterodimer (left) and the $\alpha\gamma$ heterodimer (right). Residues and structure elements of the α , β and γ subunits are colored in magenta, green and cyan, respectively.



Supplementary Fig. S5 Sequence alignment of the α , β and γ subunits of human NAD-IDH (HsIDH3) and the ScIDH1 and ScIDH2 subunits of *S. cerevisiae* NAD-IDH. The $\beta \delta$ and $\beta 7$ strands of the clasp domains which form the heterodimer-heterodimer interfaces are highlighted with black boxes. The residues of the γ subunit involved in the heterotetramer-heterotetramer interactions are indicated with cyan triangles, and the residues of the β subunit involved in the heterotetramer-heterotetramer interactions are indicated with green triangles. The C-terminal region of the β subunit that was substituted with the equivalent of the α subunit is highlighted with a green box.



a

Supplementary Fig. S6 Structural comparison between human NAD-IDH (HsIDH3) and S. cerevisiae

NAD-IDH. (a) Comparison of the overall structures of the apo β -mutant HsIDH3 (up panel) and the apo yeast NAD-IDH (PDB code: 3BLX) (low panel) in two different orientations. The color coding of the subunits is shown above. The N-terminal regions of the two γ subunits and the corresponding two ScIDH1 subunits are colored in blue, and the C-terminal regions of the two β subunits and the corresponding two ScIDH1 subunits are colored in red. The clasp domains of the $\alpha\beta$ and $\alpha\gamma$ heterodimers and the ScIDH1/ScIDH2 heterodimers are indicated with dashed ovals. (b) Interactions at the heterodimer-heterodimer interface in the apo yeast NAD-IDH, showing a high similarity with those in the apo HsIDH3 (Fig. 2b). (c) Interactions between the N-terminal of one ScIDH1 subunit of one heterotetramer (in blue) and the back cleft of one ScIDH1 subunit of the other heterotetramer (in cyan) in the apo yeast NAD-IDH, showing a high similarity of one heterotetramer (in blue) and the back cleft of one ScIDH1 subunit of the other heterotetramer (in cyan) in the apo yeast NAD-IDH, showing a high similarity different orientations are indicated with dashed lines. (d) Structural comparisons of the ScIDH1/ScIDH2 heterodimer in the apo and CIT-bound (PDB code: 3BLV) yeast NAD-IDH with the $\alpha\beta$ heterodimer (left panel) and the $\alpha\gamma$ heterodimer (right panel) in the apo HsIDH3 at the heterodimer interfaces. The color coding of the subunits is shown above. The key residues at the active site (Tyr126 of the α subunit or Tyr142 of the ScIDH2 subunit) are shown with side chains.